Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold
โ Scribed by Eric D. Jones; Nick Vandegraaff; Giang Le; Neil Choi; William Issa; Katherine Macfarlane; Neeranat Thienthong; Lisa J. Winfield; Jonathan A.V. Coates; Long Lu; Xinming Li; Xiao Feng; Changjiang Yu; David I. Rhodes; John J. Deadman
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 813 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0960-894X
No coin nor oath required. For personal study only.
โฆ Synopsis
HIV integrase inhibitors based on a novel bicyclic pyrimidinone core is presented. Nine variations of the core scaffold are evaluated leading to optimization of the 6:6 core giving compound 48 with an EC 50 of 3 nM against wild type HIV infected T-cells.
๐ SIMILAR VOLUMES
HIV-1 integrase (IN), one of the essential enzymes in HIV infection, has been validated as a target for HIV treatment. While more than 20 drugs have been approved by the FDA to treat HIV/AIDS, only one drug, Raltegravir (1), was approved as an IN inhibitor. The rapid mutation of the virus, which lea
Integration of a DNA copy of the HIV-1 genome is required for viral replication and pathogenicity, and this highly specific molecular process is mediated by the virus-encoded integrase protein. The requirement for integration, combined with the lack of a known analogous process in mammalian cells, m
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.